UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 102

Sortiert nach

Phase II Trial of Continuous Dose-Intense Temozolomide in Recurrent Malignant Glioma: RESCUE Study

Journal of clinical oncology, 2010-04, Vol.28 (12), p.2051-2057

2010

Link zum Volltext

Verfügbarkeit prüfen

Machine learning models for identifying predictors of clinical outcomes with first-line immune checkpoint inhibitor therapy in advanced non-small cell lung cancer

Scientific reports, 2022-10, Vol.12 (1), p.17670-13, Article 17670

2022

Link zum Volltext

Verfügbarkeit prüfen

Impact of the treatment crossover design on comparative efficacy in EMPOWER-Lung 1: Cemiplimab monotherapy as first-line treatment of advanced non-small cell lung cancer

Frontiers in oncology, 2023-04, Vol.12, p.1081729-1081729

2023

Link zum Volltext

Verfügbarkeit prüfen

Network meta-analysis of immune-oncology monotherapy as first-line treatment for advanced non-small-cell lung cancer in patients with PD-L1 expression ⩾50

Therapeutic advances in medical oncology, 2022, Vol.14, p.175883592211050-17588359221105024

2022

Link zum Volltext

Verfügbarkeit prüfen

Phase II Multicenter Trial of Anthracycline Rechallenge With Pegylated Liposomal Doxorubicin Plus Cyclophosphamide for First-Line Therapy of Metastatic Breast Cancer Previously Treated With Adjuvant Anthracyclines

Journal of clinical oncology, 2009-12, Vol.27 (35), p.5906-5910

2009

Link zum Volltext

Verfügbarkeit prüfen

Response to Letter to the Editor

Journal of thoracic oncology, 2023-07, Vol.18 (7), p.e74-e75

2023

Link zum Volltext

Verfügbarkeit prüfen

The RECITE Study: A Canadian Prospective, Multicenter Study of the Incidence and Severity of Residual Neuromuscular Blockade

Anesthesia and analgesia, 2015-08, Vol.121 (2), p.366-372

2015

Link zum Volltext

Verfügbarkeit prüfen

Cemiplimab Plus Chemotherapy Versus Chemotherapy Alone in Advanced NSCLC: 2-Year Follow-Up From the Phase 3 EMPOWER-Lung 3 Part 2 Trial

Journal of thoracic oncology, 2023-06, Vol.18 (6), p.755-768

2023

Link zum Volltext

Verfügbarkeit prüfen

Trends in real-world biomarker testing and overall survival in US patients with advanced non-small-cell lung cancer

Future oncology (London, England), 2022-12, Vol.18 (39), p.4385-4397

2022

Link zum Volltext

Verfügbarkeit prüfen

Characterizing the Shifting Real-World Treatment Landscape by PD-L1 Testing Status and Expression Level in Advanced Non-Small Cell Lung Cancer

Advances in therapy, 2022-10, Vol.39 (10), p.4645-4662

2022

Link zum Volltext

Verfügbarkeit prüfen

Phase II study of targeted therapy with temozolomide in acute myeloid leukaemia and high‐risk myelodysplastic syndrome patients pre‐screened for low O 6 ‐methylguanine DNA methyltransferase expression

British journal of haematology, 2014-12, Vol.167 (5), p.664-670

2014

Link zum Volltext

Verfügbarkeit prüfen

Real-World Outcomes and Prognostic Factors Among Patients with Advanced Non-Small Cell Lung Cancer and High PD-L1 Expression Treated with Immune Checkpoint Inhibitors as First-Line Therapy

Cancer management and research, 2022-01, Vol.14, p.3191-3202

2022

Link zum Volltext

Verfügbarkeit prüfen

A phase II, open label, monotherapy study of liposomal doxorubicin in patients with metastatic malignant melanoma

Investigational new drugs, 2007-04, Vol.25 (2), p.155-159

2007

Link zum Volltext

Verfügbarkeit prüfen

Efficacy of pegylated liposomal doxorubicin (PLD) plus carboplatin in ovarian cancer patients who recur within six to twelve months: A phase II study

Gynecologic oncology, 2009-09, Vol.114 (3), p.410-414

2009

Link zum Volltext

Verfügbarkeit prüfen

Chemosensitized radiosurgery for recurrent brain metastases

Journal of neuro-oncology, 2012-11, Vol.110 (2), p.265-270

2012

Link zum Volltext

Verfügbarkeit prüfen

Phase II study of targeted therapy with temozolomide in acute myeloid leukaemia and high-risk myelodysplastic syndrome patients pre-screened for low O(6) -methylguanine DNA methyltransferase expression

British journal of haematology, 2014-12, Vol.167 (5), p.664-670

2014

Link zum Volltext

Verfügbarkeit prüfen

Haemonchus contortus: Selection at a Glutamate-Gated Chloride Channel Gene in Ivermectin- and Moxidectin-Selected Strains

Experimental parasitology, 1998-09, Vol.90 (1), p.42-48

1998

Link zum Volltext

Verfügbarkeit prüfen

CemiplimAb-rwlc survivorship and epidemiology (CASE): A prospective study of safety and efficacy of cemiplimab in patients with advanced basal cell carcinoma in a real-world setting

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.TPS9614-TPS9614

2023

Link zum Volltext

Verfügbarkeit prüfen

Phase II study of targeted therapy with temozolomide in acute myeloid leukaemia and high‐risk myelodysplastic syndrome patients pre‐screened for low O6‐methylguanine DNA methyltransferase expression

British journal of haematology, 2014-12, Vol.167 (5), p.664-670

2014

Link zum Volltext

Verfügbarkeit prüfen

Peripheral myeloid cells as prognostic markers in patients (pts) with non-small cell lung cancer (NSCLC) treated with cemiplimab: Pooled analysis of EMPOWER-Lung 1 and EMPOWER-Lung 3 phase 3 trials

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.9028-9028

2023

Link zum Volltext

Verfügbarkeit prüfen

Network meta-analysis (NMA) of immuno-oncology (IO) monotherapy as first-line (1L) treatments (txs) for advanced non-small cell lung cancer (NSCLC) with PD-L1 expression ≥50

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.e21091-e21091

2021

Link zum Volltext

Verfügbarkeit prüfen

Cemiplimab monotherapy as first-line (1L) treatment of patients with brain metastases from advanced non-small cell lung cancer (NSCLC) with programmed cell death-ligand 1 (PD-L1) ≥ 50%: EMPOWER-Lung 1 subgroup analysis

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.9085-9085

2021

Link zum Volltext

Verfügbarkeit prüfen

Real-World Outcomes and Prognostic Factors Among Patients with Advanced Non-Small Cell Lung Cancer and High PD-LI Expression Treated with Immune Checkpoint Inhibitors as First-Line Therapy

Cancer management and research, 2022-11, Vol.14, p.3191

2022

Link zum Volltext

Verfügbarkeit prüfen

Efficacité d’un programme de soutien infirmier à l’intention de patientes atteintes d’un cancer de l’ovaire récidivant qui reçoivent un traitement à base de doxorubicine liposomale pégylée (Caelyx®/Doxil®)

Canadian oncology nursing journal, 2007-10, Vol.17 (3), p.137-140

2007

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 102

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(91)
Mit Volltextzugriff
(91)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(49)
Life Sciences & Biomedicine
(37)
Humans
(29)
Oncology
(18)
Male
(15)
Female
(11)
Middle Aged
(11)
Adult
(9)
Physical Sciences
(9)
Aged
(8)
Animals
(8)
Chemotherapy
(8)
Megavoltage Cone-Beam Ct
(8)
Radiology, Nuclear Medicine & Medical Imaging
(7)
Biological And Medical Sciences
(6)
Engineering
(6)
Patients
(6)
Prospective Studies
(6)
Technology
(6)
Chemistry
(5)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Phase II Trial of Continuous Dose-Intense Temozolomide in Recurrent Malignant Glioma: RESCUE Study

Machine learning models for identifying predictors of clinical outcomes with first-line immune checkpoint inhibitor therapy in advanced non-small cell lung cancer

Impact of the treatment crossover design on comparative efficacy in EMPOWER-Lung 1: Cemiplimab monotherapy as first-line treatment of advanced non-small cell lung cancer

Network meta-analysis of immune-oncology monotherapy as first-line treatment for advanced non-small-cell lung cancer in patients with PD-L1 expression ⩾50

Phase II Multicenter Trial of Anthracycline Rechallenge With Pegylated Liposomal Doxorubicin Plus Cyclophosphamide for First-Line Therapy of Metastatic Breast Cancer Previously Treated With Adjuvant Anthracyclines

Response to Letter to the Editor

The RECITE Study: A Canadian Prospective, Multicenter Study of the Incidence and Severity of Residual Neuromuscular Blockade

Cemiplimab Plus Chemotherapy Versus Chemotherapy Alone in Advanced NSCLC: 2-Year Follow-Up From the Phase 3 EMPOWER-Lung 3 Part 2 Trial

Trends in real-world biomarker testing and overall survival in US patients with advanced non-small-cell lung cancer

Characterizing the Shifting Real-World Treatment Landscape by PD-L1 Testing Status and Expression Level in Advanced Non-Small Cell Lung Cancer

Phase II study of targeted therapy with temozolomide in acute myeloid leukaemia and high‐risk myelodysplastic syndrome patients pre‐screened for low O 6 ‐methylguanine DNA methyltransferase expression

Real-World Outcomes and Prognostic Factors Among Patients with Advanced Non-Small Cell Lung Cancer and High PD-L1 Expression Treated with Immune Checkpoint Inhibitors as First-Line Therapy

A phase II, open label, monotherapy study of liposomal doxorubicin in patients with metastatic malignant melanoma

Efficacy of pegylated liposomal doxorubicin (PLD) plus carboplatin in ovarian cancer patients who recur within six to twelve months: A phase II study

Chemosensitized radiosurgery for recurrent brain metastases

Phase II study of targeted therapy with temozolomide in acute myeloid leukaemia and high-risk myelodysplastic syndrome patients pre-screened for low O(6) -methylguanine DNA methyltransferase expression

Haemonchus contortus: Selection at a Glutamate-Gated Chloride Channel Gene in Ivermectin- and Moxidectin-Selected Strains

CemiplimAb-rwlc survivorship and epidemiology (CASE): A prospective study of safety and efficacy of cemiplimab in patients with advanced basal cell carcinoma in a real-world setting

Phase II study of targeted therapy with temozolomide in acute myeloid leukaemia and high‐risk myelodysplastic syndrome patients pre‐screened for low O6‐methylguanine DNA methyltransferase expression

Circulating tumor DNA (ctDNA) dynamics and survival outcomes in patients (pts) with advanced non-small cell lung cancer (aNSCLC) and high (>50%) programmed cell death-ligand 1 (PD-L1) expression, randomized to cemiplimab (cemi) vs chemotherapy (chemo)

Peripheral myeloid cells as prognostic markers in patients (pts) with non-small cell lung cancer (NSCLC) treated with cemiplimab: Pooled analysis of EMPOWER-Lung 1 and EMPOWER-Lung 3 phase 3 trials

Network meta-analysis (NMA) of immuno-oncology (IO) monotherapy as first-line (1L) treatments (txs) for advanced non-small cell lung cancer (NSCLC) with PD-L1 expression ≥50

Cemiplimab monotherapy as first-line (1L) treatment of patients with brain metastases from advanced non-small cell lung cancer (NSCLC) with programmed cell death-ligand 1 (PD-L1) ≥ 50%: EMPOWER-Lung 1 subgroup analysis

Real-World Outcomes and Prognostic Factors Among Patients with Advanced Non-Small Cell Lung Cancer and High PD-LI Expression Treated with Immune Checkpoint Inhibitors as First-Line Therapy

Efficacité d’un programme de soutien infirmier à l’intention de patientes atteintes d’un cancer de l’ovaire récidivant qui reçoivent un traitement à base de doxorubicine liposomale pégylée (Caelyx®/Doxil®)

Suchergebnisse filtern